BIIB•benzinga•
CHMP Recommends EU Approval For Eisai's Leqembi To Treat Early Alzheimer's Disease In Apolipoprotein E ε4 Non-Carriers And Heterozygotes; Leqembi, A Monoclonal Antibody, Shown To Slow Cognitive Decline
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 14, 2024 by benzinga